Critical Analysis: Neuphoria Therapeutics (NASDAQ:NEUP) vs. Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Risk & Volatility

Humacyte has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Profitability

This table compares Humacyte and Neuphoria Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

Insider & Institutional Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Humacyte and Neuphoria Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04 million	71.02	-$40.83 million	($0.49)	-1.06
Neuphoria Therapeutics	$1.17 million	16.05	-$13.45 million	($6.22)	-0.56

Neuphoria Therapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Humacyte and Neuphoria Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1	0	6	0	2.71
Neuphoria Therapeutics	1	2	0	0	1.67

Humacyte presently has a consensus target price of $6.54, suggesting a potential upside of 1,154.39%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 101.73%. Given Humacyte’s stronger consensus rating and higher probable upside, research analysts clearly believe Humacyte is more favorable than Neuphoria Therapeutics.

Summary

Humacyte beats Neuphoria Therapeutics on 9 of the 14 factors compared between the two stocks.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.